Autonomix Medical
Lori Bisson is the Chief Executive Officer at Autonomix Medical Inc, where innovative technologies for sensing and treating disorders relating to the nervous system are being developed. With a background in finance and accounting, Lori has held various executive roles in companies such as Soliton, Inc., Moleculin Biotech, Inc., and Condon & Company. Lori's experience also includes working as a Director at Moleculin, LLC in the field of drug development. Lori obtained their BBA in Accounting from Baylor University.
This person is not in any teams
Autonomix Medical
Autonomix (Nasdaq: AMIX) is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.